重组人血管内皮抑制素在消化道恶性肿瘤中的临床应用  

Clinical Application of Recombinant Human Endostatin in Gastrointestinal Malignancies

作　　者：胡爽 赖军明 丁江华[1] HU Shuang;LAI Junming;DING Jianghua(Department of Oncology,the 171 st Hospital of Chinese People’s Liberation Army,Jiujiang 332000,China;Medical Department of Graduate School of Nanchang University,Nanchang 330006,China)

机构地区：[1]中国人民解放军第171医院肿瘤科,江西九江332000 [2]南昌大学研究生院医学部,南昌330006

出　　处：《实用临床医学（江西）》2017年第11期100-103,共4页Practical Clinical Medicine

摘　　要：重组人血管内皮抑制素(商品名:恩度)是一种抗血管生成的泛靶点靶向药物。近年来,恩度用于治疗消化道恶性肿瘤的研究逐渐增多,本文回顾了恩度在胃癌、结直肠癌、肝癌、食管癌、胆系肿瘤等消化道恶性肿瘤中的临床应用,发现患者有效率、生存期均有所提高,且毒副反应并未增加。期待更多随机、双盲、对照、多中心的临床研究,为恩度治疗消化道恶性肿瘤提供理论依据。Recombinant human endostatin(Endostar)is a broad spectrum drug targeting angiogenesis.In recent years,Endostar has been widely used in the treatment of gastrointestinal malignancies in experimental studies.This paper reviews the clinical application of Endostar in gastric cancer,colorectal cancer,hepatic carcinoma,esophageal carcinoma,biliary tract cancer and other gastrointestinal malignancies.These results show that the response rate and survival time are improved and adverse reactions were not increased by treatment with Endostar.However,more randomized,double-blind,controlled and multicentre clinical studies should be performed to provide a theoretical basis for treating gastrointestinal malignancies with Endostar.

关 键 词：重组人血管内皮抑制素 消化道恶性肿瘤 临床应用 

分 类 号：R735[医药卫生—肿瘤]